Trial Profile
A Multicenter, Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of NKTR-102 (PEG-Irinotecan) When Given on a Q14 Day or a Q21 Day Schedule in Patients With Metastatic or Locally Advanced Platinum-Resistant Ovarian Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Dec 2021
Price :
$35
*
At a glance
- Drugs Etirinotecan pegol (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Sponsors Nektar Therapeutics
- 19 Jul 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database.
- 18 Sep 2017 Results published in the Gynecologic Oncology
- 14 Aug 2014 Status changed from active, no longer recruiting to completed as reported by alTrials.gov.